CAM
OTLK icon

Cormorant Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Cormorant Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-788
Closed -$23K – 76
2019
Q3 		$23K Hold
788
– – ﹤0.01% 75
2019
Q2 		$32K Buy
+788
New +$36.7K ﹤0.01% 71
2018
Q1 		– Sell
-191
Closed -$40K – 56
2017
Q4 		$40K Sell
191
-3,521
-95% -$730K ﹤0.01% 49
2017
Q3 		$814K Sell
3,712
-2,554
-41% -$465K 0.14% 48
2017
Q2 		$1.01M Hold
6,266
– – 0.17% 63
2017
Q1 		$2.69M Buy
6,266
+1,058
+20% +$526K 0.39% 54
2016
Q4 		$2.51M Sell
5,208
-1,212
-19% -$678K 0.34% 56
2016
Q3 		$4.37M Hold
6,420
– – 0.48% 54
2016
Q2 		$3.49M Buy
+6,420
New +$3.83M 0.5% 52

Other funds holding OTLK

LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DI
DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return

Cormorant Asset Management's OTLK Position: Q4 2019 in Review

Cormorant Asset Management sold out of Outlook Therapeutics (OTLK) in Q4 2019, closing a stake of 788 shares — an estimated $23K sold.

Cormorant Asset Management first reported a position in OTLK in Q2 2016 and held it in 9 quarters. The position peaked at $4.37M in Q3 2016. 17 funds tracked by Wall St. Rank hold OTLK as of Q4 2019.

  • Cormorant Asset Management reported no remaining Outlook Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Cormorant Asset Management sold 788 Outlook Therapeutics shares in Q4 2019, an estimated $23K.
  • Cormorant Asset Management first reported a position in Outlook Therapeutics in Q2 2016 and held it in 9 quarters.
  • Cormorant Asset Management's Outlook Therapeutics position peaked at $4.37M in Q3 2016.
  • 17 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.